Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07837934
PHASE2

Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes

Sponsor: Tan Tock Seng Hospital

View on ClinicalTrials.gov

Summary

This study will test whether a low-cost anti-inflammatory medicine called colchicine can help protect the blood vessels of people with type 2 diabetes. Diabetes speeds up hardening of the arteries (atherosclerosis), partly because of ongoing low-grade inflammation. Colchicine has already been shown to help prevent heart attacks and strokes in people who already have heart disease; this study looks at whether it can also help prevent early blood vessel damage before heart disease develops. Around 300 adults with type 2 diabetes will be randomly assigned to take colchicine or a placebo (dummy pill) once daily for 24 weeks, in addition to their usual diabetes and heart-risk medications. Neither participants nor the study team will know who is taking colchicine or placebo. The main measurement will be the change in the thickness of the wall of the neck (carotid) artery, measured by ultrasound, which is an early sign of blood vessel disease. The study will also look at markers of inflammation in the blood, blood vessel stiffness and function, and changes in the gut bacteria.

Official title: The Role of Colchicine in Preventing Atherosclerotic Cardiovascular Disease in Type 2 Diabetes (Col-DM Study)

Key Details

Gender

All

Age Range

21 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2025-07-24

Completion Date

2027-07-31

Last Updated

2026-09-24

Healthy Volunteers

No

Interventions

DRUG

Colchicine 0.5 MG Oral Tablet Once Daily

For 24 weeks

DRUG

Placebo

Matched placebo tablets (identical in size, shape, taste, and packaging to colchicine), once daily, for 24 weeks

Locations (1)

Tan Tock Seng Hospital

Singapore, Singapore, Singapore